1University
of California, San Francisco, San Francisco, CA, United States; 2Stanford
University, Palo Alto, CA, United States
Renal cell carcinomas (RCCs) are a heterogeneous group of tumors with a wide range of aggressiveness. There is a current lack of noninvasive biomarkers that can confidently predict the behavior of RCCs to guide treatment selection and to monitor treatment response. Development of clinically relevant biomarkers of RCC aggressiveness and response to novel therapeutics requires robust models that recapitulate the human situation. The purpose of this study is to establish both an ex vivo and an in vivo model of RCCs using patient-derived tissue slices for metabolism studies in conjunction with hyperpolarized (HP) 13C MR.